Davies, M.J., D'Alessio, D.A., Fradkin, J., Kernan, W.N., Mathieu, C., Mingrone, G., et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European association for the study of diabetes (EASD). Diabetologia 61 (2018), 2461–2498.
American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S55–S64.
Butler, J., Hamo, C.E., Filippatos, G., Pocock, S.J., Bernstein, R.A., Brueckmann, M., et al. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail 19 (2017), 1390–1400.
Scheen, A.J., Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res 122 (2018), 1439–1459.
Gerstein, H.C., Miller, M.E., Genuth, S., Ismail-Beigi, F., Buse, J.B., Goff, D.C. Jr, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364 (2011), 818–828.
Cefalu, W.T., Kaul, S., Gerstein, H.C., Holman, R.R., Zinman, B., Skyler, J.S., et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors’ Expert Forum. Diabetes Care 41 (2018), 14–31.
Riddle, M.C., Ambrosius, W.T., Brillon, D.J., Buse, J.B., Byington, R.P., Cohen, R.M., et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 33 (2010), 983–990.
Hempe, J.M., Liu, S., Myers, L., McCarter, R.J., Buse, J.B., Fonseca, V., The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. Diabetes Care 38 (2015), 1067–1074.
Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 373 (2015), 2117–2128.
Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
Marso, S.P., Bain, S.C., Consoli, A., Eliaschewitz, F.G., Jodar, E., Leiter, L.A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
Holman, R.R., Bethel, M.A., Mentz, R.J., Thompson, V.P., Lokhnygina, Y., Buse, J.B., et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377 (2017), 1228–1239.
Hernandez, A.F., Green, J.B., Janmohamed, S., D'Agostino, R.B. Sr., Granger, C.B., Jones, N.P., et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392 (2018), 1519–1529.
Scheen, A.J., Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Res Clin Pract. 143 (2018), 88–100.
van Baar, M.J.B., van Ruiten, C.C., Muskiet, M.H.A., van Bloemendaal, L., RG IJ, van Raalte, DH., SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care 41 (2018), 1543–1556.
Kuo, S., Ye, W., Duong, J., Herman, W.H., Are the favorable cardiovascular outcomes of empagliflozin treatment explained by its effects on multiple cardiometabolic risk factors? A simulation of the results of the EMPA-REG OUTCOME trial. Diabetes Res Clin Pract 141 (2018), 181–189.
Nauck, M.A., Meier, J.J., Cavender, M.A., Abd El Aziz, M., Drucker, D.J., Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 136 (2017), 849–870.
Wang, Q., Liu, L., Gao, L., Li, Q., Cardiovascular safety of GLP-1 receptor agonists for diabetes patients with high cardiovascular risk: A meta-analysis of cardiovascular outcomes trials. Diabetes Res Clin Pract 143 (2018), 34–42.
